Latest Csl News

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.

Whitefield Industrials reports a $10.5 million net profit for H1 2026, with a strong 17.1% annualised return over three years, maintaining its track record of benchmark outperformance and announcing a 10.5 cent fully franked dividend.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

CSL Limited has updated its dividend announcement for the first half of FY2025, confirming a USD 1.62 per share ordinary dividend and clarifying currency payment arrangements for global shareholders.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Katana Capital Limited reported a 10.63% gross investment return for the 2025 financial year, surpassing the All Ordinaries index by 1.16%. The fund’s defensive strategy and valuation discipline helped navigate a volatile market environment.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited has announced an unfranked ordinary dividend of USD 1.62 per share for the first half of 2025, with payments scheduled in multiple currencies depending on shareholder location.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

WAM Leaders Limited reported a strong $63.8 million net profit for FY2025 and declared a fully franked final dividend of 4.7 cents per share, despite its investment portfolio underperforming the benchmark index.

AMCIL Limited reported a net profit of $6.7 million for FY2025, down from $7.5 million the previous year, and announced a fully franked total dividend of 6.5 cents per share, boosted by a special capital gains payout.